Literature DB >> 26464752

Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus.

Ashraf Tabll1, Aymn T Abbas1, Sherif El-Kafrawy1, Ahmed Wahid1.   

Abstract

Hepatitis C virus (HCV) is a major health problem worldwide. Early detection of the infection will help better management of the infected cases. The monoclonal antibodies (mAb) of mice are predominantly used for the immunodiagnosis of several viral, bacterial, and parasitic antigens. Serological detection of HCV antigens and antibodies provide simple and rapid methods of detection but lack sensitivity specially in the window phase between the infection and antibody development. Human mAb are used in the immunotherapy of several blood malignancies, such as lymphoma and leukemia, as well as for autoimmune diseases. In this review article, we will discuss methods of mouse and human monoclonal antibody production. We will demonstrate the role of mouse mAb in the detection of HCV antigens as rapid and sensitive immunodiagnostic assays for the detection of HCV, which is a major health problem throughout the world, particularly in Egypt. We will discuss the value of HCV-neutralizing antibodies and their roles in the immunotherapy of HCV infections and in HCV vaccine development. We will also discuss the different mechanisms by which the virus escape the effect of neutralizing mAb. Finally, we will discuss available and new trends to produce antibodies, such as egg yolk-based antibodies (IgY), production in transgenic plants, and the synthetic antibody mimics approach.

Entities:  

Keywords:  Hepatitis C virus; Immunodiagnosis; Immunotherapy; Monoclonal antibodies

Year:  2015        PMID: 26464752      PMCID: PMC4598607          DOI: 10.4254/wjh.v7.i22.2369

Source DB:  PubMed          Journal:  World J Hepatol


  131 in total

1.  Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles.

Authors:  Sandra Ciesek; Sandra Westhaus; Melanie Wicht; Ilka Wappler; Sylvana Henschen; Christoph Sarrazin; Nabila Hamdi; Ahmed I Abdelaziz; Christian P Strassburg; Heiner Wedemeyer; Michael P Manns; Thomas Pietschmann; Thomas von Hahn
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Applied biotechnology for production of immunoglobulin Y specific to hepatitis A virus.

Authors:  Vanessa Salete de Paula; Alexandre dos Santos da Silva; Gentil Arthur Lins Bentes Mendonça de Vasconcelos; Ezio Tavares Iff; Maria Eduarda Monteiro Silva; Livia Abud Kappel; Paula Borba Cruz; Marcelo Alves Pinto
Journal:  J Virol Methods       Date:  2010-10-29       Impact factor: 2.014

Review 3.  Perspectives for a vaccine against hepatitis C virus.

Authors:  S Abrignani; M Houghton; H H Hsu
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

4.  Examination of the buoyant density of hepatitis C virus by the polymerase chain reaction.

Authors:  R J Carrick; G G Schlauder; D A Peterson; I K Mushahwar
Journal:  J Virol Methods       Date:  1992-09       Impact factor: 2.014

5.  Determination of the role for CD21 during Epstein-Barr virus infection of B-lymphoblastoid cells.

Authors:  D R Martin; R L Marlowe; J M Ahearn
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

6.  Prophylaxis and therapy of pandemic H1N1 virus infection using egg yolk antibody.

Authors:  Yuan-e Yang; Junlin Wen; Suqing Zhao; Kun Zhang; Yingliang Zhou
Journal:  J Virol Methods       Date:  2014-05-29       Impact factor: 2.014

7.  Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.

Authors:  Zhen-yong Keck; Jinming Xia; Yong Wang; Wenyan Wang; Thomas Krey; Jannick Prentoe; Thomas Carlsen; Angela Ying-Jian Li; Arvind H Patel; Stanley M Lemon; Jens Bukh; Felix A Rey; Steven K H Foung
Journal:  PLoS Pathog       Date:  2012-04-12       Impact factor: 6.823

8.  Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein.

Authors:  Gabrielle Vieyres; Jean Dubuisson; Arvind H Patel
Journal:  J Gen Virol       Date:  2010-11-17       Impact factor: 3.891

9.  Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions.

Authors:  Zhen-Yong Keck; Jinming Xia; Zhaohui Cai; Ta-Kai Li; Ania M Owsianka; Arvind H Patel; Guangxiang Luo; Steven K H Foung
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

Authors:  Alexander W Tarr; Ania M Owsianka; Judith M Timms; C Patrick McClure; Richard J P Brown; Timothy P Hickling; Thomas Pietschmann; Ralf Bartenschlager; Arvind H Patel; Jonathan K Ball
Journal:  Hepatology       Date:  2006-03       Impact factor: 17.425

View more
  2 in total

1.  Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.

Authors:  Ahmed Atef Mesalam; Isabelle Desombere; Ali Farhoudi; Freya Van Houtte; Lieven Verhoye; Jonathan Ball; Jean Dubuisson; Steven K H Foung; Arvind H Patel; Mats A A Persson; Geert Leroux-Roels; Philip Meuleman
Journal:  Virology       Date:  2017-11-10       Impact factor: 3.616

2.  Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies.

Authors:  Soma Das; Ranajoy Mullick; Anuj Kumar; Himani Tandon; Mihika Bose; K Gouthamchandra; Madhavi Chandra; Bagepally Ravishankar; M N Khaja; Narayanaswamy Srinivasan; Saumitra Das; Shaila Melkote Subbarao; Anjali Anoop Karande
Journal:  J Gen Virol       Date:  2017-05-08       Impact factor: 3.891

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.